299 related articles for article (PubMed ID: 15029034)
1. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Edan G
Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
[TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Edan G; Comi G; Le Page E; Leray E; Rocca MA; Filippi M;
J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1344-50. PubMed ID: 21436229
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Gonsette RE
Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561
[TBL] [Abstract][Full Text] [Related]
7. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
Jarius S; Hohlfeld R; Voltz R
MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
10. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
11. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
12. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
Cendrowski W
Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
[TBL] [Abstract][Full Text] [Related]
14. Review of mitoxantrone in the treatment of multiple sclerosis.
Jeffery DR; Herndon R
Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone for multiple sclerosis in clinical practice.
Rizvi SA; Zwibel H; Fox EJ
Neurology; 2004 Dec; 63(12 Suppl 6):S25-7. PubMed ID: 15623666
[TBL] [Abstract][Full Text] [Related]
16. [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Edan G
Rev Neurol (Paris); 2006 Feb; 162(2):185-94. PubMed ID: 16518258
[TBL] [Abstract][Full Text] [Related]
17. [2012: Update on diagnosis and treatment of multiple sclerosis].
Havla J; Kümpfel T; Hohlfeld R
Dtsch Med Wochenschr; 2012 Apr; 137(17):894-9. PubMed ID: 22492476
[No Abstract] [Full Text] [Related]
18. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
19. [New therapeutic strategies in multiple sclerosis].
Berger E; Rumbach L
Rev Med Interne; 1999 Aug; 20 Suppl 3():346s-350s. PubMed ID: 10480185
[TBL] [Abstract][Full Text] [Related]
20. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]